Drug Device Combination Products Market Report Scope and Overview:

The Drug Device Combination Products Market was valued at USD 187.00 Billion in 2025 and is projected to reach USD 367.86 Billion by 2035, registering a CAGR of 7.00% between 2026 and 2035.

The Drug Device Combination Products Market is gaining pace as biopharmaceutical companies increasingly package therapies with purpose-built delivery hardware rather than treat devices as an afterthought to the molecule. Growth is supported by the rapid shift of biologic and GLP-1 therapies toward self-administration, which raises demand for prefilled syringes, autoinjectors and wearable on-body injectors that reduce clinic burden and support adherence outside hospital settings. Regulatory bodies overseeing combination products are pushing manufacturers toward tighter human-factors validation and usability evidence, while device makers and drugmakers continue forming manufacturing alliances to secure capacity for large-volume biologics, reinforcing sustained equipment, component and assembly demand across the value chain.

⮞In November 2025, SHL Medical marked a global milestone of 1.5 billion autoinjectors shipped since its founding, crediting its Molly platform and Reunite autoinjector with supporting the launch of more than sixty combination products worldwide.

U.S. Drug Device Combination Products Market Outlook

The U.S. Drug Device Combination Products Market was valued at approximately USD 68.02 Billion in 2025 and is projected to reach USD 127.70 Billion by 2035, registering a CAGR of 6.50% from 2026 to 2035.

The U.S. Drug Device Combination Products Market draws on a large base of biopharmaceutical manufacturers, device developers and contract partners equipped to scale combination products for sizeable patient populations managing diabetes, obesity and chronic inflammatory conditions. The Food and Drug Administration's Office of Combination Products maintains an established review pathway that gives sponsors clarity on drug-device applications, supporting faster clinical adoption once approvals clear. A deep bench of device assemblers, fill-finish specialists and prefilled-component suppliers keeps U.S. capacity ahead of demand, while payer coverage for self-injectable biologics sustains steady patient uptake across hospital, retail and home-care channels nationwide.

⮞In July 2026, Enable Injections and Sanofi secured approval for Sarclisa Escena delivered through the CirCLIQ on-body injector, which the companies described as the first anticancer treatment administered through an on-body device, replacing hours-long infusions with a short, hands-free injection.

By Product Type: Prefilled Syringes & Autoinjectors Lead, Transdermal Patches Grow Fastest

Prefilled syringes and autoinjectors held the leading position in the Drug Device Combination Products Market, supported by their central role in delivering biologics, insulin and GLP-1 therapies that patients now self-administer at home. Their compact, ready-to-use design removes compounding steps found with vials and traditional syringes, lowering dosing errors and training time. Manufacturers have also standardized barrel and needle-shield designs around widely used autoinjector platforms, letting drugmakers qualify new molecules against existing hardware rather than building bespoke devices, which shortens timelines and keeps supply chains concentrated among specialized device partners.

Transdermal patches are expanding at the fastest pace as drugmakers favor non-invasive delivery for chronic pain, hormone therapy and neurological conditions where steady, sustained drug release reduces peak-trough fluctuations tied to oral dosing. Patches avoid needles entirely, widening patient acceptance among those who are needle-averse or manage long-term regimens requiring daily application. Advances in adhesive chemistry and microneedle arrays are letting formulators deliver larger-molecule actives that previously required injection, pulling new therapeutic categories into patch form.

⮞In January 2026, Becton Dickinson and Ypsomed advanced their device partnership with a 5.5 milliliter version of the BD Neopak XtraFlow prefillable syringe built for compatibility with Ypsomed's YpsoMate 5.5 autoinjector, targeting larger-volume biologic formulations for self-injection.

By Route of Administration: Parenteral Leads, Transdermal Grows Fastest

Parenteral delivery held the leading position in the Drug Device Combination Products Market, reflecting the breadth of injectable formats, prefilled syringes, autoinjectors, infusion pumps and implantable drug-eluting devices, now built around standardized hardware platforms. Biologic and GLP-1 therapies dosed by injection account for the largest share of combination-product volume, and manufacturers continue to qualify new molecules against established parenteral hardware rather than developing bespoke delivery systems. This scale advantage, combined with mature regulatory pathways for injectable combination products, keeps parenteral delivery the dominant route across nearly every therapeutic area covered by the market.

Transdermal delivery is growing fastest as drugmakers pursue non-invasive administration for chronic pain, hormone therapy and neurological conditions where steady drug release avoids the peak-trough fluctuations associated with injections or oral dosing. Needle-averse patients and those managing long-term regimens increasingly favor patch-based therapy, widening acceptance beyond its traditional base. Advances in adhesive chemistry and microneedle array design are also enabling larger-molecule actives that previously required injection to be reformulated for transdermal delivery, pulling new drug classes into the fastest-growing route of administration.

By Application: Diabetes Leads, Oncology Grows Fastest

Diabetes maintains the largest application share in the Drug Device Combination Products Market because insulin pens, patch pumps and connected injectors have become the default delivery format for a patient population that must dose multiple times daily for decades. Long-standing reimbursement pathways, broad physician familiarity and established manufacturing scale keep per-unit costs low, which supports continued volume even as GLP-1 therapies introduce adjacent demand. Chronic, lifelong therapy duration gives diabetes device programs a predictable, recurring revenue base that device makers prioritize when allocating new assembly and fill-finish capacity.

Oncology is growing fastest as injectable and infused cancer therapies increasingly migrate toward subcutaneous formulations paired with on-body or handheld delivery devices, cutting infusion-chair time and easing capacity pressure on oncology clinics. Combination products let patients receive treatments outside traditional infusion settings, which lowers total cost of care and improves convenience for regimens that previously required extended hospital visits. Growing clinical evidence supporting subcutaneous bioequivalence to intravenous dosing is encouraging oncology drug sponsors to pursue device-enabled reformulations across an expanding set of approved biologic therapies.

By End User: Hospitals & Clinics Lead, Home Care Settings Grow Fastest

Hospitals and clinics retain the largest end-user share because complex combination products, including drug-eluting stents, infusion pumps and certain oncology injectors, require clinical supervision during administration or implantation. Institutional purchasing processes also favor established device brands with proven safety records and dedicated technical support, reinforcing demand continuity for suppliers already qualified within hospital formularies. Specialized storage, cold-chain handling and trained nursing staff further concentrate administration of higher-complexity combination products within hospital and clinic settings rather than less-equipped sites of care.

Home care settings are expanding fastest as payers and health systems push chronic-disease management outside hospitals to control costs, supported by autoinjectors, patch pumps and on-body injectors engineered specifically for layperson use. Device makers have invested heavily in simplified, low-training-burden designs with audible or visual dose confirmation, which builds patient confidence for unsupervised self-administration. Aging populations managing multiple chronic conditions simultaneously are also driving demand for home-compatible devices that reduce travel burden and clinic congestion while maintaining consistent therapy adherence.

Regional Analysis

North America Drug Device Combination Products Market Insights

North America held the largest share of the Drug Device Combination Products Market in 2025, at 41.85% of global value, reflecting the region's depth of biopharmaceutical manufacturing, device-development expertise and contract assembly capacity spanning the United States and Canada. Predictable review timelines under the FDA's Office of Combination Products encourage sustained device-development investment, since sponsors can plan clinical and manufacturing programs around a defined regulatory pathway rather than case-by-case negotiation. Broad commercial insurance and government payer coverage for self-injectable biologics and insulin delivery systems further supports steady patient access across hospital, retail pharmacy and home-care channels.

The region's manufacturing base continues expanding as device makers build new prefillable-component and assembly capacity domestically rather than relying solely on imported subassemblies, shortening supply chains for high-volume GLP-1 and biologic programs. Canada contributes a smaller but stable share, anchored by biosimilar manufacturing and public health system procurement. Strong clinical-trial activity concentrated in the United States also keeps new combination products entering the regulatory pipeline earlier than in most other regions, reinforcing North America's position as the primary launch market for novel delivery platforms.

⮞In April 2026, Ypsomed opened a new tool-manufacturing facility in Solothurn, Switzerland, to support pen and autoinjector mold production for its wider manufacturing network, including a new site under construction in Holly Springs, North Carolina, expanding its U.S. production footprint.

Europe Drug Device Combination Products Market Insights

Europe holds the second-largest share of the Drug Device Combination Products Market, supported by a long-established base of device manufacturers, prefillable-syringe producers and contract development organizations concentrated in Germany, Switzerland and Ireland. Centralized and national regulatory pathways under the EU Medical Device Regulation give sponsors defined combination-product requirements, even as compliance timelines have lengthened component qualification cycles across the region. Reimbursed national health systems in Germany, France and the United Kingdom continue supporting broad patient access to self-injectable biologics and insulin delivery devices.

Regional device makers continue expanding capacity to serve both European and export demand, with several manufacturers investing in dedicated production halls for autoinjectors, pen-injector platforms and prefillable syringes across multiple countries. Growing biosimilar manufacturing across Germany and Ireland is reinforcing device-assembly demand as patents on major biologics expire and new manufacturers enter the field. Switzerland remains a concentrated hub for precision device engineering, supplying autoinjector platforms used by drugmakers across multiple therapeutic areas well beyond the region's own borders, reinforcing its export-oriented manufacturing role.

⮞In March 2026, West Pharmaceutical Services opened a 165,000-square-foot expansion at its Damastown, Dublin site under its West Vantage contract-services business, adding automation and drug-handling capacity to support high-volume injectable therapies including diabetes and obesity treatments.

Asia Pacific Drug Device Combination Products Market Insights

Asia Pacific is the fastest-growing region in the Drug Device Combination Products Market, registering a projected CAGR of approximately 10.20% from 2026 to 2035, as China, Japan and India expand domestic biologics manufacturing and insulin delivery device production. Rising diabetes prevalence across the region, combined with growing middle-class access to self-injectable therapies, is pushing both multinational and domestic device makers to localize production rather than rely on imported components. Government health programs in several countries are also expanding reimbursement coverage for chronic-disease delivery devices, widening the addressable patient base.

Japan's long-standing precision-manufacturing base continues supplying components and finished devices both domestically and for export, while China's expanding contract development sector is attracting multinational device makers seeking lower-cost assembly capacity close to a large patient population. India's growing injectable-drug manufacturing industry is adding device-assembly capability alongside its established generic drug-substance base. Rising clinical trial activity across the region is also accelerating local regulatory familiarity with combination-product requirements, shortening the time needed to bring new delivery platforms to regional markets.

⮞In March 2026, Terumo outlined a $500 million expansion plan covering an acquired German drug-product plant and $350 million directed toward advancing CDMO and drug-delivery capabilities, including autoinjector and safety-device assembly, across its three manufacturing sites in Japan.

MEA and Latin America Drug Device Combination Products Market Insights

Latin America is building a growing manufacturing presence within the Drug Device Combination Products Market, led by Brazil and Mexico, as multinational drugmakers expand regional production to serve large diabetes and obesity patient populations without relying solely on imports. Government procurement programs and public health systems in both countries continue widening access to insulin delivery devices, while growing private manufacturing investment is gradually localizing component and assembly capacity that previously depended on supply from North America and Europe.

The Middle East and Africa region remains smaller in absolute terms but is expanding as Gulf Cooperation Council countries invest in domestic pharmaceutical manufacturing to reduce import dependence and diversify away from oil-linked economies. Saudi Arabia and the United Arab Emirates are the primary growth centers, supported by national healthcare modernization programs that are widening coverage for chronic-disease management devices. South Africa continues to anchor manufacturing and distribution activity across the broader African market, though device-assembly capacity across the continent remains comparatively limited.

⮞In April 2025, Novo Nordisk announced an investment of roughly USD 1.1 billion to expand its Montes Claros, Brazil production site, adding aseptic processing and quality-control capacity to manufacture injectable treatments including GLP-1 products for obesity and other chronic diseases.

Market Dynamics

Growth Drivers: Shift Toward Self-Administered Biologic and GLP-1 Therapies

Growing prescription volumes for biologic and GLP-1 therapies are pushing drugmakers to pair molecules with autoinjectors, prefilled syringes and pen injectors that let patients dose themselves outside clinical settings. This shift reduces per-patient healthcare system costs tied to clinic visits and nursing time, which gives payers a direct financial incentive to favor combination-product formulations over vial-and-syringe alternatives wherever clinically appropriate. Rising chronic-disease prevalence, particularly obesity and diabetes, is expanding the patient population eligible for self-injectable regimens, sustaining long-term device demand.

Device standardization around proven autoinjector and pen platforms is lowering development risk for drugmakers, who can qualify new therapies against existing hardware instead of engineering bespoke delivery systems from scratch. This has encouraged closer, earlier collaboration between pharmaceutical sponsors and device specialists during clinical development rather than retrofitting delivery hardware after approval. Growing manufacturing capacity investment by established device makers is also easing supply constraints that previously limited how quickly new combination products could scale to commercial volumes.

⮞In October 2025, Stevanato Group opened a production expansion at its Bad Oeynhausen, Germany facility, adding more than 2,500 square meters of cleanroom space to manufacture its Aidaptus autoinjector and Alina pen-injector platforms for both proprietary and contract-manufacturing customers.

Restraints: Regulatory Complexity and Rising Combination-Product Compliance Costs

Combination products face dual regulatory oversight spanning drug and device review pathways, which lengthens development timelines compared with single-mode drugs or standalone devices. Sponsors must generate human-factors usability evidence demonstrating that intended users, including elderly or visually-impaired patients, can operate devices safely without clinical supervision, adding testing cycles and cost before filing. Divergent regional requirements between major regulatory authorities further complicate global launch planning, often forcing design adjustments market by market rather than a single worldwide device configuration.

Component and device-assembly costs have also risen as specialized materials, tamper-evident features and connected-device electronics become more common across premium combination products, pressuring margins for both device makers and drugmakers. Smaller biopharmaceutical companies with limited in-house device expertise often depend entirely on external partners for design and manufacturing, which can create supply bottlenecks during periods of high demand. Extended qualification and validation cycles required after any component change further slow the pace at which manufacturers can respond to shifting demand or introduce design improvements.

Opportunities: Expansion of Connected and Home-Care Delivery Platforms

Growing payer and provider interest in shifting chronic-disease management into home settings is creating opportunities for device makers to introduce connected autoinjectors and patch pumps that track adherence and dosing in real time. These platforms let pharmaceutical companies and health systems monitor patient compliance remotely, supporting value-based care models that reward measurable treatment outcomes. Expanding smartphone connectivity and digital health infrastructure across both developed and emerging markets is widening the addressable base for connected delivery devices beyond early adopter segments.

Emerging markets across Asia Pacific, Latin America and the Middle East present substantial unaddressed opportunity as rising incomes and expanding insurance coverage make self-injectable biologics newly affordable for larger patient populations. Localized manufacturing partnerships are letting device makers reduce costs enough to compete in price-sensitive markets while still meeting international quality standards. Continued innovation in transdermal and microneedle delivery also opens opportunities to bring entirely new drug classes into non-invasive combination-product formats for the first time.

Drug Device Combination Products Market key players are:

• Becton, Dickinson and Company

• SHL Medical AG

• Ypsomed Holding AG

• West Pharmaceutical Services, Inc.

• Stevanato Group S.p.A.

• Gerresheimer AG

• Terumo Corporation

• Enable Injections, Inc.

• Aptar Pharma (AptarGroup, Inc.)

• Nipro Corporation

• Phillips-Medisize (a Molex company)

• Teva Pharmaceutical Industries Ltd.

• Medtronic plc

• Abbott Laboratories

• Boston Scientific Corporation

• Johnson & Johnson MedTech

• GSK plc

• AstraZeneca plc

• Catalent, Inc.

• Vetter Pharma-Fertigung GmbH & Co. KG

Drug Device Combination Products Market Report Scope: